Xenetic Biosciences, INC 10-K annual reports

Xenetic Biosciences, Inc. has amended its annual report to provide detailed disclosures on executive compensation, board governance, and significant consulting agreements with related parties.

Xenetic Biosciences, Inc. reported a significant reduction in net loss for 2025, driven by increased royalty revenue and a successful $4.0 million public offering, as it continues to advance its proprietary DNase technology for solid tumors.

Xenetic Biosciences files an amendment to its 2024 annual report to include details on equity award grant practices and updated certifications.

Xenetic Biosciences files an amendment to its 2024 annual report to include information previously omitted regarding directors, executive officers, compensation, and related matters.

Xenetic Biosciences' 2024 10-K filing highlights the company's focus on advancing its DNase technology for cancer treatment amid ongoing financial losses.

Xenetic Biosciences has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

Xenetic Biosciences outlines its capital stock, warrant details, and regulatory compliance measures in its annual 10-K filing.